Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review

BACKGROUND: Vedolizumab is a gut-selective anti-lymphocyte trafficking agent approved for the treatment of moderate to severely active inflammatory bowel disease (IBD: ulcerative colitis [UC] and Crohn’s disease [CD]). METHODS: A systematic literature review (SLR) of real-world studies was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Dipen, Martin, Stephan, Luo, Michelle, Ursos, Lyann, Lirio, Richard A, Kamble, Pravin, Wang, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802433/
https://www.ncbi.nlm.nih.gov/pubmed/36777427
http://dx.doi.org/10.1093/crocol/otac020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802433/
https://www.ncbi.nlm.nih.gov/pubmed/36777427
http://dx.doi.org/10.1093/crocol/otac020

Ejemplares similares